![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1542516
¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)Global Biologics Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
»ý¹°Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 167¾ï 7,000¸¸ ´Þ·¯¿¡¼ 2032³â¿¡´Â ¾à 479¾ï 2,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³âÀÇ CAGRÀº 11.07%ÀÔ´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹÁ¦Á¶Àº ¹ÙÀÌ¿ÀÀǾàǰÀÇ »ý»ê ¹× Á¦Á¶ °øÁ¤À» Àü¹® ¼öŹÁ¦Á¶±â°ü(CMO)¿¡ À§Å¹ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. »ý¹°Á¦Á¦´Â ´Ü¹éÁú, Ç×ü, ¹é½Å, ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦¿Í °°Àº »ý¹° À¯·¡ÀÇ º¹ÀâÇÑ Ä¡·á Á¦Ç°ÀÔ´Ï´Ù. Á¦¾à»ç, »ý¸í°øÇÐ ±â¾÷ ¹× Çмú±â°üÀº CMOÀÇ Àü¹® Áö½Ä, ¿ª·® ¹× ÀÎÇÁ¶ó¸¦ Ȱ¿ëÇÏ¿© È¿À²ÀûÀÌ°í ºñ¿ë È¿À²ÀûÀ¸·Î ´ë±Ô¸ð·Î »ý¹°Á¦Á¦¸¦ »ý»êÇÒ ¼ö ÀÖ½À´Ï´Ù.
»ý¹°Á¦Á¦ÀÇ È¿´É°ú ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý¿¡ µû¸¥ ¼ö¿ä Áõ°¡·Î ÀÎÇØ È¿À²ÀûÀÎ Á¦Á¶ ´É·ÂÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. Àü¹® ¼öŹÁ¦Á¶¾÷ü(CMO)¿¡ »ý¹°Á¦Á¦ Á¦Á¶¸¦ À§Å¹ÇÔÀ¸·Î½á Á¦¾à»ç´Â ºñ¿ë È¿À²¼º°ú À¯¿¬¼ºÀ» ³ôÀ̰í ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÏ¸ç ¼ö¿ä¿¡ µû¶ó »ý»ê·®À» Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. CMO´Â ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁذú ǰÁú º¸ÁõÀ» ÃæÁ·½ÃÄÑ ±ÔÁ¦ Áؼö¿Í Á¦Ç°ÀÇ ¾ÈÀü¼º°ú À¯È¿¼º À¯Áö¸¦ º¸ÀåÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ ±â¼ú ¹ßÀüÀº ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ÀÇ È¿À²¼º°ú »ý»ê¼ºÀ» ´õ¿í Çâ»ó½Ã۰í, Á¦¾àȸ»ç¿Í CMOÀÇ Çù·ÂÀû ÆÄÆ®³Ê½ÊÀº ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ°í °øÁ¤À» °£¼ÒÈÇÕ´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à »ê¾÷ ¼¼°è ½ÃÀå È®´ë¿Í ÇÔ²² »ý¹°Á¦Á¦¿¡ ´ëÇÑ Á߿伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ°í È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº »ý¹°Á¦Á¦ À§Å¹ »ý»ê ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦ ¼öŹÁ¦Á¶ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ ¼öŹÁ¦Á¶ ½ÃÀå º¸°í¼ÀÇ ÀÌ ¼½¼Ç¿¡¼´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ °¢ Á¦Ç° ¶Ç´Â ¼ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϰí ÇâÈÄ ±âȸ¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ »ý¹°Á¦Á¦ ¼öŹÁ¦Á¶ ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.
Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
The global demand for Biologics Contract Manufacturing Market is presumed to reach the market size of nearly USD 47.92 Billion by 2032 from USD 16.77 Billion in 2023 with a CAGR of 11.07% under the study period 2024 - 2032.
Biologics contract manufacturing refers to the outsourcing of the production and manufacturing processes of biopharmaceutical products to specialized contract manufacturing organizations (CMOs). Biologics are complex therapeutic products derived from living organisms, such as proteins, antibodies, vaccines, and cell-based therapies. It allows pharmaceutical companies, biotechnology firms, and academic institutions to leverage the expertise, capabilities, and infrastructure of CMOs to efficiently and cost-effectively produce biologics on a large scale.
The increasing demand for biological drugs, driven by their efficacy and personalized medicine approaches, fuels the need for efficient manufacturing capabilities. Outsourcing biologics production to specialized contract manufacturing organizations (CMOs) offers cost efficiency and flexibility for pharmaceutical companies, allowing them to focus on core competencies and adjust production volumes based on demand. The stringent regulatory standards and quality assurance in this manufacturing are met by CMOs, ensuring compliance with regulations and maintaining product safety and efficacy. Technological advancements in bioprocessing further enhance the efficiency and productivity of biologics manufacturing, and collaborative partnerships between pharmaceutical companies and CMOs drive innovation and streamline processes. The global market expansion of the biopharmaceutical industry, along with the growing emphasis on biologics, reinforces the need for reliable and scalable solutions.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics contract manufacturing. The growth and trends of biologics contract manufacturing industry provide a holistic approach to this study.
This section of the biologics contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Biologics Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biologics contract manufacturing market include Wuxi Biologics; Abzena Ltd.; FUJIFILM Diosynth Biotechnologies; BI BioXcellence; Lonza Group AG; Boehringer Ingelheim GmbH; Samsung Biologics; Abbvie; Catalent; Bioreliance; Eurofins CDMO; Thermo Fischer (Patheon). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.